CTOs on the Move


 
Wherever you are, exhale Therapeutic Air® to immediately access the ancient wellness art of aromatherapy. Unlike topical oils or household diffusers, MONQ® is enhanced for convenience in the modern age. Experience the most direct form of aromatherapy with MONQ Personal Diffuser.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.monq.com
  • N/A
    Goodlettsville, TN USA N/A
  • Phone: 844.936.6667

Executives

Name Title Contact Details

Similar Companies

Core Health & Fitness

Core Health & Fitness is more than gym equipment, we offer innovative solutions for all your facility needs. This is why we’ve brought together five of the most recognizable fitness brands to ensure our customers can offer their members authentic fitne...

PTPN

PTPN is a Calabasas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Registered Practical Nurses Association of Ontario

Registered Practical Nurses Association of Ontario is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carlinville Area Hospital Association, Inc

Carlinville Area Hospital Association, Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Carlinville, IL. To find more information about Carlinville Area Hospital Association, Inc, please visit www.cahcare.com

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.